Hemophilia B News and Research

RSS

Prophylaxis effective at preventing joint bleeds and preserving joint function and structure in young boys with hemophilia A

According to a new landmark study published in The New England Journal of Medicine, infusions of clotting factor VIII used preventively can significantly reduce the risk of developing joint damage associated with joint bleeding in young children with hemophilia A.

9 Aug 2007

Xenomics issued European patent for Transrenal Nucleic Acid Technology for Prenatal Diagnostics

Xenomics, Inc. has announced the issuance of its first European patent "Methods for detection of nucleic acid sequences in urine", EP 1634966 A2 that covers use of its proprietary transrenal nucleic acid technology in the area of prenatal diagnostics and genetic testing.

1 Aug 2007

Baxter receives FDA approval for new dosage of Advate for hemophilia A

Baxter Healthcare Corporation announced that the U.S. Food and Drug Administration (FDA) has approved a new 3000 IU (5mL) dosage strength of ADVATE [Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method].

12 Jul 2007

Baxter presents findings from the ADAPT study

Baxter Healthcare Corporation has announced the presentation of findings from the ADAPT (Analysis of Data from ADVATE Prospective Trials) study program database showing a statistically significant relationship between the duration of time spent with factor VIII blood levels below one international unit per deciliter (1 IU/dL, one percent of normal factor VIII level) and an increase in the annual bleed rate in people with hemophilia A.

11 Jul 2007

New platform for regulating the expression of therapeutic genes

A new platform for regulating the expression of therapeutic genes, which will have major implications for gene and cell therapy, was presented at the 10th Annual Meeting of the American Society of Gene Therapy (ASGT) in Seattle.

3 Jun 2007

FDA approves Norditropin for short stature in children with Noonan syndrome

Novo Nordisk has announced that Norditropin (somatropin[rDNA origin] injection) received U.S. Food and Drug Administration (FDA) approval for the treatment of short stature in children with Noonan syndrome.

3 Jun 2007

Study finds large number of new proteins implicated in Huntington's disease

Researchers from four organizations have identified more than 200 new proteins that bind to normal and mutant forms of the protein that causes Huntington's disease (HD).

11 May 2007

New treatments for brain hemorrhage

The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.

4 May 2007

FDA approves new treatment for von Willebrand disease

The U.S. Food and Drug Administration (FDA) has approved Humate-P (Antihemophilic Factor/von Willebrand Factor Complex) for the prevention of excessive bleeding during and after surgery in certain patients with mild to moderate and severe von Willebrand disease (vWD).

30 Apr 2007

Muscle restoration in an animal model of Duchenne muscular dystrophy

Using a new type of drug that targets a specific genetic defect, researchers at the University of Pennsylvania School of Medicine, along with colleagues at PTC Therapeutics Inc. and the University of Massachusetts Medical School, have for the first time demonstrated restoration of muscle function in a mouse model of Duchenne's muscular dystrophy (DMD).

24 Apr 2007

Scientists tackle cancer with different approaches

Studies presented at the 2007 meeting of the American Association for Cancer Research show how researchers are using the new, as well as the natural, to help design and test new drugs to treat cancer.

18 Apr 2007

Fragile X and Down syndrome appear to share common genetic cause

The two most prevalent forms of genetic mental retardation, Fragile X and Down syndromes, may share a common cause, according to researchers at Stanford University School of Medicine.

11 Apr 2007

Bayer Healthcare Pharmaceuticals launches in the U.S.

Bayer HealthCare Pharmaceuticals Inc. today announced its official U.S. launch. The new company incorporates the former Berlex Inc.into Bayer HealthCare Pharmaceuticals, as part of Bayer's acquisition of Schering AG, Germany, Berlex's former parent company.

5 Apr 2007

Increasing numbers of blood collection centers in parts of China contributing to spread of HIV

The increasing number of blood-collection centers in parts of China is posing a threat to vulnerable populations and placing them at an increased risk of HIV transmission, some Chinese HIV/AIDS advocates have said recently, the Boston Globe reports.

4 Mar 2007

Apolipoprotein C1 protein linked to elevated BMI in people of American Indian and Mexican ancestry

University of Minnesota researchers have discovered a variant of a common blood protein, apolipoprotein C1, in people of American Indian and Mexican ancestry that is linked to elevated body mass index (BMI), obesity and Type 2 diabetes.

22 Feb 2007

Alphanate approved to treat Von Willebrand disease

The U.S. Food and Drug Administration (FDA) has announced the approval of Antihemophilic Factor/von Willebrand Factor Complex (Human), Alphanate.

4 Feb 2007

Army docs use of dangerous drug labelled irresponsible and inappropriate

American soldiers critically wounded in Iraq are being treated with a potent, experimental, blood-coagulating drug despite evidence it can cause clots in the lungs, heart and brain, leading to strokes, heart attacks and death.

20 Nov 2006

Potential permanent genetic cure for hemophilia A

A discovery by Medical College of Wisconsin and BloodCenter of Wisconsin researchers in Milwaukee may be a key to a permanent genetic cure for hemophilia A patients, including a subset who do not respond to conventional blood transfusions.

3 Jul 2006

Convictions in $45 million illegal blood diversion scheme

Florida pharmaceutical wholesale distributor, convicted on March 29, 2006, of more than two hundred and forty-seven criminal counts as the result of an extensive OCI investigation of an illegal medical products diversion scheme which defrauded the Medicaid and Medicare programs of more than $45,000,000.

19 Apr 2006

Weill Cornell experts publish review of genetic medicine

In an article published in the April issue of Nature Reviews Genetics, two experts at the Weill Medical College of Cornell University sum up the achievements, challenges and promise of a burgeoning field: genetic medicine.

3 Apr 2006